The GULP1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population originating from A-549 cells, with targeted disruption of the GULP1 gene. This heterogeneous pool captures a spectrum of genetic alterations, offering a loss-of-function model that avoids clonal selection biases inherent in monoclonal lines. It is optimized for rigorous investigation of GULP1-mediated phagocytosis and apoptotic cell clearance in a human lung adenocarcinoma context.
A-549 cells are an adherent human lung adenocarcinoma epithelial line established from a 58-year-old Caucasian male. Widely used in cancer biology and respiratory research, these cells recapitulate features of alveolar type II pneumocytes and enable studies on tumor progression, metastasis, and drug response. Their robust proliferation and amenability to CRISPR-based editing make them an ideal platform for interrogating GULP1 function in lung cancer phenotypes.
Mechanistically, GULP1 encodes an adaptor protein that couples phagocytic receptors??including CED-1, LRP1, and integrins??to the DOCK180/ELMO complex, triggering Rac1 activation and Arp2/3-dependent actin polymerization. GULP1 directly interacts with CED-6, ABCA1, and Stabilin-2 to assemble phagocytic cup structures. Working in concert with ELMO1 and DOCK180, it orchestrates Rac1-dependent cytoskeletal remodeling essential for efferocytosis, cell migration, and tissue homeostasis. Consequently, GULP1 disruption severs the link between receptor engagement and Rac1, impairing actin reorganization and apoptotic cell internalization.
In the A-549 lung adenocarcinoma context, GULP1 knockout is particularly impactful because failed efferocytosis can sustain chronic inflammation and create a pro-tumorigenic milieu. Persistent uncleared debris may release damage-associated molecular patterns that enhance inflammatory signaling and drive tumor progression. Moreover, GULP1 involvement in integrin-mediated adhesion and migration suggests its loss could modify the metastatic capacity of A-549 cells. This model therefore provides a system to elucidate how defective phagocytic clearance and altered cytoskeletal dynamics shape lung adenocarcinoma pathology.
Applications for these GULP1 knockout A-549 polyclonal cells span phagocytosis assays with fluorescent targets, Western blotting, RT-qPCR, immunofluorescence, flow cytometry, and migration/invasion assays. The model is suitable for RNA-seq and proteomics analyses aimed at defining GULP1-dependent transcriptional and interactome landscapes. It also supports drug target validation and basic research into phagocytosis, apoptosis, and inflammation. As a ready-to-use knockout pool, it expedites functional studies without requiring in-house genome editing. For additional details or custom services, please contact Ascent Research.
